Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2889-2902

  Vosper, Jonathan ^a   Masuccio, Alessia ^a   Kullmann, Michael ^a   Ploner, Christian ^a   Geley, Stephan ^a   Hengst, Ludger ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cell cycle; Geranylgeranylation; Lovastatin; p27; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; F BOX PROTEIN; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; MEVINOLIN; S PHASE KINASE ASSOCIATED PROTEIN 2; ANTINEOPLASTIC AGENT; CADHERIN; CDH1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FIZZY RELATED PROTEIN; FZR1 PROTEIN, MOUSE; GERANYLGERANYLTRANSFERASE TYPE-I; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID PHOSPHATE; PROTEASOME; S PHASE KINASE ASSOCIATED PROTEIN; TRANSFERASE;

ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; RNA STABILITY; TRANSCRIPTION REGULATION; UBIQUITINATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR SUPPRESSOR GENE; U937 CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CDH1 PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; GENES, APC; HELA CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICE; NEOPLASMS; NIH 3T3 CELLS; POLYISOPRENYL PHOSPHATES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; U937 CELLS;

EID: 84923315494     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3068     Document Type: Article

References (53)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980; 77(7):3957-3961.
2. Keyomarsi K, Sandoval L, Band V and Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991; 51(13):3602-3609.
3. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel- Reid S, Freedman MH, Yeger H and Penn LZ. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001; 7(1):158-167.
4. Gauthaman K, Manasi N and Bongso A. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol. 2009; 157(6):962-973.
5. Kotamraju S, Williams CL and Kalyanaraman B. Statininduced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007; 67(15):7386-7394.
6. Bjorkhem-Bergman L, Acimovic J, Torndal UB, Parini P and Eriksson LC. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 2010; 30(4):1105-1112.
7. Vainio P LL, Mirtti T, Hilvo M, Seppanen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A, Ore.i. M, Kallioniemi O and Iljin K. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. 2011; 2(12):1176-1190.
8. Mira E C-RL, Tardaguila M, Azcoitia I, Gonzalez- Martin A, Almonacid L, Casas J, Fabrias G and Manes S. A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget. 2013; 4(12):2288-2301.
9. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005; 5(12):930-942.
10. Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012; 324(1):1-12.
11. Liao JK and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118.
12. Hengst L, Dulic V, Slingerland JM, Lees E and Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994; 91(12):5291-5295.
13. Gray-Bablin J, Rao S and Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 1997; 57(4):604-609.
14. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A and Kanwar YS. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A. 2002; 99(12):8301- 8305.
15. Hengst L and Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996; 271(5257):1861-1864.
16. Carrano AC, Eytan E, Hershko A and Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999; 1(4):193-199.
17. Tsvetkov LM, Yeh KH, Lee SJ, Sun H and Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999; 9(12):661-664.
18. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U and Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999; 1(4):207-214.
19. Kossatz U, Dietrich N, Zender L, Buer J, Manns MP and Malek NP. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 2004; 18(21):2602-2607.
20. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M and Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem. 2003; 278(28):25752-25757.
21. Lu Z and Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle. 2010; 9(12):2342-2352.
22. Rao S, Porter DC, Chen X, Herliczek T, Lowe M and Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999; 96(14):7797-7802.
23. Efuet ET and Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 2006; 66(2):1040-1051.
24. Niknejad N, Morley M and Dimitroulakos J. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem. 2007; 282(41):29748-29756.
25. Wojcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S and Jakobisiak M. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol. 2000; 32(9):957-965.
26. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, Jakel H, Kullmann M, Kriwacki RW and Hengst L. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007; 128(2):269-280.
27. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J and Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001; 98(9):5043-5048.
28. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008; 112(7):1415-1424.
29. Frescas D and Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008; 8(6):438-449.
30. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F and Krek W. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J. 2000; 19(20):5362-5375.
31. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW and Kaelin WG, Jr. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 2004; 428(6979):194-198.
32. Bashir T, Dorrello NV, Amador V, Guardavaccaro D and Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature. 2004; 428(6979):190-193.
33. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K and Nakayama KI. Degradation of p57Kip2 mediated by SCFSkp2- dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003; 100(18):10231-10236.
34. Zhang H, Kobayashi R, Galaktionov K and Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell. 1995; 82(6):915-925.
35. Berndt N, Hamilton AD and Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011; 11(11):775-791.
36. Schulman BA, Carrano AC, Jeffrey PD, Bowen Z, Kinnucan ER, Finnin MS, Elledge SJ, Harper JW, Pagano M and Pavletich NP. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature. 2000; 408(6810):381-386.
37. Ecker K and Hengst L. Skp2: caught in the Akt. Nat Cell Biol. 2009; 11(4):377-379.
38. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW and Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell. 1996; 86(2):263-274.
39. Ji P, Goldin L, Ren H, Sun D, Guardavaccaro D, Pagano M and Zhu L. Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1. J Biol Chem. 2006; 281(33):24058-24069.
40. Xu S, Abbasian M, Patel P, Jensen-Pergakes K, Lombardo CR, Cathers BE, Xie W, Mercurio F, Pagano M, Giegel D and Cox S. Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase. J Biol Chem. 2007; 282(21):15462-15470.
41. Rao S, Lowe M, Herliczek TW and Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 1998; 17(18):2393-2402.
42. Tang BK and Kalow W. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4. Eur J Clin Pharmacol. 1995; 47(5):449-451.
43. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM, Dalin M, Weinbaum C, Casey PJ, Tarkowski A, Swolin B, Young SG and Bergo MO. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest. 2007; 117(5):1294-1304.
44. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD and Saito Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem. 1997; 272(1):13-16.
45. Laufs U, Marra D, Node K and Liao JK. 3-Hydroxy-3- methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPaseinduced down-regulation of p27(Kip1). J Biol Chem. 1999; 274(31):21926-21931.
46. Hu W, Bellone CJ and Baldassare JJ. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/ CDK2 activity. J Biol Chem. 1999; 274(6):3396-3401.
47. Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A and Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Mol Cell Biol. 2009; 29(8):2254-2263.
48. Bond M, Wu YJ, Sala-Newby GB and Newby AC. Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. Cardiovasc Res. 2008; 80(2):290-298.
49. Aktories K, Wilde C and Vogelsgesang M. Rho-modifying C3-like ADP-ribosyltransferases. Rev Physiol Biochem Pharmacol. 2004; 152:1-22.
50. Fukushima H, Ogura K, Wan L, Lu Y, Li V, Gao D, Liu P, Lau AW, Wu T, Kirschner MW, Inuzuka H and Wei W. SCF-mediated Cdh1 degradation defines a negative feedback system that coordinates cell-cycle progression. Cell Rep. 2013; 4(4):803-816.
51. Sigl R, Wandke C, Rauch V, Kirk J, Hunt T and Geley S. Loss of the mammalian APC/C activator FZR1 shortens G1 and lengthens S phase but has little effect on exit from mitosis. J Cell Sci. 2009; 122(Pt 22):4208-4217.
52. Kullmann MK, Grubbauer C, Goetsch K, Jakel H, Podmirseg SR, Trockenbacher A, Ploner C, Cato AC, Weiss C, Kofler R and Hengst L. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle. 2013; 12(16):2625-2635.
53. Barisic M, Sohm B, Mikolcevic P, Wandke C, Rauch V, Ringer T, Hess M, Bonn G and Geley S. Spindly/ CCDC99 is required for efficient chromosome congression and mitotic checkpoint regulation. Mol Biol Cell. 2010; 21(12):1968-1981.